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PERIPHERAL BLOOD BIOMARKERS IN YOUTH WITH BIPOLAR 
DISORDER: A SYSTEMATIC REVIEW 
 
JENNIFER N. ORUEBOR 
 
 
ABSTRACT 
 Bipolar disorder (BD) is a chronic, progressive illness characterized by 
fluctuations in mood. It is associated with psychosocial and cognitive impairment that 
can affect a person’s life at home, at work or school, and in interpersonal relationships. 
Children and adolescents diagnosed with BD experience similar functional impairments 
and risk for suicidal thoughts or actions compared to adults. Additionally, they are at an 
increased risk for poorer prognosis during adulthood given the negative outcomes 
associated with early illness onset, delayed treatment, misdiagnosis, and longer illness 
duration. The etiology and pathophysiology of bipolar disorder is incompletely 
understood. Peripheral blood biomarkers can provide insight into the mechanisms 
underlying the disease and can aid in identifying at-risk individuals, making an accurate 
diagnosis, monitoring illness activity and improving therapeutic intervention. A PubMed 
search was carried out and 12 studies were identified that assessed potential peripheral 
blood biomarkers in children and adolescents with bipolar disorder. These studies suggest 
that fatty acid biostatus, markers of lipid and protein oxidation, markers of inflammation 
and immune disturbance, neurotrophic factors and enzymes related to inflammation may 
serve as biomarkers of BD. These potential biomarkers of the disorder warrant further 
		 vi 
study in youth with BD. Current findings support a staging hypothesis of BD wherein 
cumulative episodes lead to disruptions of the pathways associated with the disorder and 
thus greater impairment in patients farther from their disease onset. However, these and 
other biomarkers will need to be evaluated in larger, longitudinal studies to validate their 
use and expand knowledge in the field.  
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INTRODUCTION 
Bipolar disorder (BD) is a psychiatric illness characterized by episodes of mania, 
hypomania and major depression interspersed between a baseline period of symptom 
recovery called euthymia. The Diagnostic and Statistical Manual of Mental Disorders 5th 
ed. (DSM-V) outlines two distinct types of BD. The key diagnostic criteria for bipolar 
disorder type I (BD-I) is the presence of manic episodes that last a minimum of seven 
days or manic symptoms that are so severe that hospitalization is required. A manic 
episode is a period of elevated, expansive, or irritable mood and includes symptoms such 
as grandiosity, decreased need for sleep, talkativeness, flight of ideas, distractibility or 
increased risky behavior. Depressive episodes can also be seen in BD-I but are not 
required for diagnosis. Bipolar disorder type II (BD-II) is diagnosed by the presence of 
hypomanic episodes that last at least four days and major depressive episodes that lasts 
for at least two weeks. A major depressive episode is a period of depressed mood and 
includes symptoms such as loss of interest or pleasure in activities, significant weight 
change, insomnia or hypersomnia, fatigue, feelings of worthlessness or thoughts of death 
(Diagnostic and Statistical Manual of Mental Disorders, 2013). BD has a lifetime 
prevalence of 4.4% among US adults with the highest prevalence seen in those 18 to 29 
years of age (Figure 1). Globally, BD contributes to a disease burden measured at 9.92 
million disability-adjusted life years with over 45.5 million cases reported in 2017 (GBD 
2017 DALYs and HALE Collaborators et al., 2018; GDB 2017 Disease and Injury 
Incidence and Prevalence Collaborators et al., 2018). 
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Figure 1: Lifetime Prevalence of Bipolar Disorder in the United States by Age and 
Gender. The highest prevalence is among those aged 18 to 29 with an overall prevalence 
of 4.4%. Data is from the National Comorbidity Survey Replication (NCS-R). (Harvard 
Medical School, 2007) 
 
The “bipolar spectrum” refers to the well-defined BD-I and BD-II diagnoses, as 
well as other conditions involving mood swings that do not meet the duration or severity 
requirements to indicate a manic, hypomanic or depressive episode. Cyclothymic 
disorder, for instance, involves hypomanic and depressive symptoms that occur for at 
least two years (one year in children). The presence of bipolar and related disorder 
symptoms that do not satisfy duration or severity requirements for BD-I, BD-II or 
cyclothymia can be captured under the diagnosis other specified bipolar and related 
disorder (OSB-RD) along with a specifier to explain why it does not fall under one of the 
previous three diagnoses. The diagnosis OSB-RD replaced the previous umbrella term for 
subsyndromal bipolar symptoms used in the Diagnostic and Statistical Manual of Mental 
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Disorders 4th ed. (DSM-IV) called bipolar disorder not otherwise specified (BD-NOS). 
There continues to be concern about whether the changes in the DSM-V have improved 
or worsened the accurate diagnosis of bipolar and related disorders (Angst, 2013). 
  
Course of Illness in Bipolar Disorder 
The course of BD is chronic and progressive meaning that it is expected to get 
worse over time without intervention. While BD does consist of “episodes” during which 
symptoms are at their worst, it includes both prodromal and residual symptoms that occur 
outside of an active mood episode causing continuous impairment (Kaya, Aydemir, & 
Selcuki, 2007; Keitner et al., 1996). As reviewed in 2013, one of the reasons that the true 
burden of BD is underestimated is a misunderstanding of its chronicity (Fagiolini et al., 
2013). An extended course of illness in BD is supported by several findings including 
one study which followed patients with BD for over 10 years and found that they were 
symptomatically ill nearly 50% of the time and a separate study that found the median 
time to recovery from onset of a mood episode was 13 weeks (Judd et al., 2002; Solomon 
et al., 2010). BD is debilitating, interfering with a person’s social, academic and 
occupational functioning. Patients with BD report a range of difficulty in psychosocial 
functioning, including trouble in their interpersonal relationships, decreased enjoyment in 
recreational activities, decline in job status and income, and family/marital problems. 
These functional impairments are present in spite of clinical remission and are often 
related to subthreshold symptoms or comorbidities, such as substance abuse or anxiety 
disorders (Sanchez-Moreno et al., 2009; Zarate, Land, Tohen, & Cavanagh, 2000). 
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Neurocognitive impairment is observed across mood states in patients with BD and is 
also associated with psychosocial impairment (Malhi et al., 2007; Mur, Portella, 
Martinez-aran, Pifarre, & Vieta, 2009).   
Several clinical staging models have been put forth in BD to capture the 
progressive nature of the illness; these range from an “at-risk” stage, wherein symptoms 
may not have manifested but there is risk of developing the disorder due to factors such 
as family history, to a “late” stage, wherein symptoms are persistent and unremitting 
(Salagre et al., 2018). A study on patients with unipolar and bipolar affective disorders 
found that recurrence was more likely with increased number of mood episodes (Kessing, 
Hansen, Andersen, & Angst, 2004). Longer illness duration also puts patients at risk for 
cognitive decline which has been associated with increased number of manic and 
depressive episodes, and is observed even after prolonged asymptomatic periods (López-
Jaramillo et al., 2010; Zubieta, Huguelet, O’Neil, & Giordani, 2001). Additionally, in a 
study comparing early-stage and late-stage BD patients to siblings of BD patients and to 
healthy controls, late-stage BD patients were found to score worse on a measure of social 
functioning than early-stage BD patients. Both patient groups scored worse than siblings 
and controls (Tatay-Manteiga et al., 2018). This points to the progressive course of BD 
with significant impairment related to longer illness duration. In addition to functional 
impairment, an especially concerning aspect of BD is the risk of suicidal thoughts or 
actions. A significant portion of the disease burden stems from the fact that suicide is 
within the top twenty leading causes of death worldwide (World Health Organization, 
2017); between 25% to 50% of patients with BD will attempt suicide at least once in their 
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lifetime, and between 8% and 19% will complete suicide (Latalova, Kamaradova, & 
Prasko, 2014). The progression of the disorder after onset may be partially explained by 
allostatic load, a wear and tear of the systems that work to maintain balance through 
changes in the body (McEwen & Wingfield, 2003). These systems can become 
overwhelmed by multiple insults leading to pathological consequences. Patients with BD 
demonstrate changes in mediators of allostasis, including components of the 
hypothalamic pituitary adrenal (HPA) axis, immune system, inflammation, oxidative 
stress, and trophic factors (Flavio Kapczinski et al., 2008). Applying the concept of 
allostatic load can be used to understand the progression of BD, as well as the increased 
comorbidity and mortality observed in this patient population (Figure 2). 
The etiology of BD is not fully understood, but there is evidence that onset 
involves both genetic and environmental factors. First, BD is highly heritable as 
evidenced by twin studies (McGuffin et al., 2003). Second, there are several 
environmental factors that have been associated with the disorder. Prenatal famine (A. S. 
Brown, van Os, Driessens, Hoek, & Susser, 2000) and preterm birth (Nosarti et al., 2012) 
have both been found to increase risk of developing BD. Additionally, psychosocial 
stressors such as negative life events or sleep disturbance are associated with the onset of 
an affective episode (Johnson, 2005). It is likely that multiple genetic and environmental 
factors interact leading to the onset of BD. One study found that patients with BD-I who 
had a single nucleotide polymorphism (SNP) in the gene for Brain-Derived Neurotrophic 
Factor (BDNF) were found to be more likely to develop a depressive episode after a 
stressful life event (Hosang et al., 2010). In another study by the same author, the impact 
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of stressful life events was also found to be moderated by a SNP in the catechol-O-
methyltransferase (COMT) gene in BD patients (Hosang, Fisher, Cohen‐Woods, 
McGuffin, & Farmer, 2017). Additionally, polymorphisms in the CACNA1C gene, 
which codes for the alpha 1 subunit of the L-type voltage-gated calcium channel, and the 
GABRB1 gene, which encodes the beta 1 subunit of the gamma-aminobutyric acid a-
class receptor, are both associated with BD risk (Arts, Simons, & Os, 2013; The 
Wellcome Trust Case Control Consortium, 2007). More research in the area of gene-
environment interaction as it pertains to BD is needed (Uher, 2014).  	  
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Figure 2. Mediators of Allostasis Involved in BD. The mediators of allostasis observed 
in BD are associated with illness progression, comorbidity and excess mortality in 
patients with BD. Reproduced from (Muneer, 2016b).
 
Bipolar Disorder in Children and Adolescents 
The average age of onset for BD is in the mid-to-late twenties, yet many adult BD 
patients report onset before the age of 21 (Baldessarini et al., 2010; Perlis et al., 2004; 
Post et al., 2010). It is unclear what causes early-onset BD, but a parental history of a 
mood disorder or other psychosis such as schizophrenia has been associated with earlier 
age of onset (Chengappa et al., 2003). Earlier illness onset is a risk factor for poorer 
prognosis. Patients with early-onset BD are more likely to have  comorbid anxiety or 
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substance abuse disorders, illness recurrences and shorter periods of euthymia, and are 
more likely to attempt suicide (Grunebaum et al., 2006; Hawton, Sutton, Haw, Sinclair, 
& Harriss, 2005; Perlis et al., 2004). Poorer outcomes in adulthood may be due to, in part, 
the treatment delay seen in patients with earlier illness onset (Post et al., 2010). 
Successful intervention in the earlier stages may be key to preventing the severe 
functional impairment observed in late-stage BD by reducing the number of mood 
episodes, increasing the period of euthymia and decreasing symptom severity. Given that 
poorer outcomes are associated with early illness onset, delayed treatment, and a longer 
duration of illness, children and adolescents with BD are an especially vulnerable 
subpopulation of patients with the disorder.  
The existence of BD in children and adolescents (collectively referred to as 
“youth” throughout this paper) was previously a point of contention due to the perceived 
lack of clinical cases demonstrating manic-depressive psychosis among children 
(Anthony & Scott, 1960). One of the first studies to provide evidence that manic 
episodes, and thus BD, was present in children was the work of Janet Wozniak and 
associates in 1995. In the study, children aged twelve or younger whom were referred to 
the clinic for psychiatric treatment were evaluated for manic symptoms. The cohort 
included 43 children (16%) who met criteria for mania as outlined out in the Diagnostic 
and Statistical Manual of Mental Disorders 3rd edition, Revised (DSM-III-R). Those 
diagnosed with mania were also co-morbid for attention deficient hyperactivity disorder 
(ADHD). However, compared with non-manic patients with ADHD, those with mania 
demonstrated poorer psychosocial functioning and higher rates of major depression 
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(Wozniak et al., 1995). Further, the irritability observed in manic participants was more 
severe than what was expected for normal childhood development or non-manic ADHD 
symptomatology. It is now accepted that mania is observed in children and adolescents 
and when controlling for methodological differences there is consistency within the 
literature on pediatric-onset bipolar disorder (PBD) with regard to symptom presentation, 
clinical features and co-morbid illnesses (Kowatch, Youngstrom, Danielyan, & Findling, 
2005).   
From a clinician’s standpoint, the diagnostic criteria for BD are the same in youth 
and adults. However, special considerations must be given when identifying symptoms of 
manic/hypomanic or depressive episodes in children and adolescents. These 
considerations include developmental stage, overlap of symptoms with abnormal mood, 
comorbid psychiatric disorders, environmental and cultural context, medical illness and 
illicit/prescription drug use, and decline in functioning (Birmaher, 2013). For example, 
when identifying the symptoms of increased energy or distractibility it is important that 
the symptoms (1) occur as a break from age-appropriate baseline behavior, and a child’s 
baseline may include a co-occurring illness such as ADHD or oppositional defiant 
disorder (ODD) and (2) occur simultaneously with a period of mood change (Goldstein, 
2012). Generally, the longitudinal course of BD is similar in youth and adults, however 
there are subtle differences. Particularly, youth spend more time symptomatic (includes 
subsyndromal and syndromal symptoms) and display more mixed/rapid cycling mood 
episodes (Birmaher et al., 2009). An episode with mixed features refers to a period when 
symptoms meet the criteria for a manic/hypomanic or depressive episode and also include 
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symptoms of the opposite polarity (Diagnostic and Statistical Manual of Mental 
Disorders, 2013). Rapid cycling refers to four or more mood episodes in a 12-month 
period (Kramlinger & Post, 1996). One study found at an 8-year follow up that youth 
with BD-I spent 60.2% of their time in a mood episode and that youth with BD continue 
experiencing mood episodes into adulthood (Geller, Tillman, Bolhofner, & Zimerman, 
2008). Additionally, of the youth with BD-NOS, 40% can be expected to convert to BD-I 
or BD-II (Birmaher et al., 2009).  
The lifetime prevalence of BD-I or BD-II in a representative U.S. sample of 
adolescents aged 13 to 18 was 2.9 percent (Merikangas et al., 2010). Youth with BD 
suffer from cognitive (Elias et al., 2017) and psychosocial impairment (Best, Bowie, 
Naiberg, Newton, & Goldstein, 2017) making the course of PBD debilitating, similar to 
the course of adult-onset BD. Suicide is one of the top ten leading causes of death for 
those between the ages of 10 to 24 in the United States (Figure 2). Risk factors for 
attempted suicide among patients with BD include early onset age, mixed affective states, 
and rapid cycling (Hawton et al., 2005). Thus, in addition to the functional impairment 
associated with PBD, youth who are diagnosed with BD are at an increased risk for 
attempting suicide in their lifetime. Given the severe impact of early onset and delayed 
treatment on the course of illness, it is important that BD is diagnosed appropriately in 
children and adolescents and that therapeutic interventions are started before of soon after 
symptoms become syndromal. Peripheral biomarkers of the disorder may hold the key to 
such intervention. 
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Figure 3: Distribution of 10 Leading Causes of Deaths, ages 10 – 24. In the United 
States, suicide is the second leading cause of death among people between the ages of 10 
and 24. Reproduced from (Heron, 2017)
 
Biomarkers of Bipolar Disorder 
 The term “biomarker” may have a slightly different meaning depending on who is 
providing the definition, but it has shown up in scientific literature since at least 1980. 
The National Institutes of Health has previously defined a biomarker as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group, 2001). Other definitions assert that a biomarker 
should be able to be measured accurately and reproducibly, especially in clinical research 
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(Strimbu & Tavel, 2010). Biomarkers of disease are useful in a variety of ways. They can 
be used to identify individuals who are at risk for developing a disease, they can be used 
to make an accurate diagnosis and monitor disease progression, and they can be used in 
the development and clinical implementation of therapeutic interventions. Biomarkers 
can be collected by several means including blood, urine, saliva or hair samples, tissue 
biopsies, neuroimaging or cerebral spinal fluid. Once collected and assessed, biomarkers 
can provide information about disease processes centrally and throughout the body. In 
deciding to measure biomarkers in biomedical research, researchers must weigh 
disadvantages such as the time required for collection, cost of analysis and cost of storing 
samples. Further, researchers must take care to hold the measurement of biomarkers to 
the same standard as any variable in research and eliminate the possibility of bias or 
measurement error (Mayeux, 2004). Once biomarkers are validated through research, 
they can be used in clinical settings.  
 Biomarkers are important to understand the molecular changes that occur in BD, 
and a growing portion of the literature on BD has attempted to identify and validate 
potential biomarkers of the disorder (Duong, Syed, & Scola, 2015). Peripheral blood 
biomarkers, in particular, are easily obtained through venipuncture and are relatively 
inexpensive to analyze. When combined with clinical features, peripheral biomarkers can 
also be used to stage BD and understand its progression (Flávio Kapczinski et al., 2009). 
There is substantially less literature on peripheral biomarkers in youth with BD compared 
to that on adults with BD. This is an important deficit to address because not only are 
children and adolescents with BD particularly vulnerable to worse outcomes in 
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adulthood, but also studying this population can provide useful insight into the 
mechanisms of the disorder. This is because youth are closer to their illness onset, 
arguably have less allostatic load from repeated affective episodes, and are less likely to 
have a history of prolonged medication usage. The objective of this systematic review is 
to locate and examine the literature on peripheral blood biomarkers that have been 
identified in observational studies on children and adolescents with BD and to assess 
what these biomarkers suggest about the pathophysiology of BD in youth and adults. 
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METHODS 	
Search Strategy 
  Studies were identified by searching the PubMed database for peer-reviewed 
journal articles that were published between January 1, 1966 and December 15, 2018. 
The combination of keywords used was “bipolar disorder” AND (“children” OR 
“pediatric” OR “youth” OR “juvenile” OR “childhood” OR “adolescent”) AND 
(“biomarker” OR “marker” OR “peripheral biomarker” OR “blood biomarker” OR 
“peripheral blood mononuclear cells” OR “oxidative stress” OR “nitrosative stress” OR 
“cellular metabolism” OR “inflammation” OR “mitochondrial dysfunction” OR 
“mitochondrial dynamics” OR “apoptosis”).  	
Eligibility Criteria 
 Studies were included if they were an English-language, observational study 
assessing at least one biomarker in peripheral blood samples from participants with BD 
that were between the ages of 9 to 29. After screening, 12 articles remained and the full 
text of each was read. The reference section from each article was also reviewed to 
ensure that no eligible articles were excluded.  
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PUBLISHED STUDIES 	 The	results	of	the	literature	search	revealed	that	there	are	relatively	few	studies	on	peripheral	blood	biomarkers	in	children	and	adolescents	with	BD	compared	to	that	available	on	adults.	This	may	be	due	to,	in	part,	the	controversy	that	surrounded	PBD	until	more	recently.	Efforts	have	expanded	to	understand	the	prevalence	and	etiopathology	of	PBD,	but	these	are	lagging	behind	the	strides	made	in	adult	BD	research.	Additionally,	research	on	peripheral	blood	biomarkers	in	PBD	may	be	hindered	by	reduced	access	to	healthcare	among	families	of	youth	with	BD,	misdiagnosis	when	symptoms	are	present,	and	a	fear	of	needles	required	for	venipuncture.	The	studies	identified	through	the	literature	search	are	reviewed	below	roughly	organized	by	area	of	interest.	There	were	some	participant	and	methodological	differences	between	studies	including	the	use	of	a	control	group,	age	range,	current	mood	state	of	BD	patients	and	the	diagnostic	criteria	that	was	used	(Table	1).			
Table 1. Descriptions of Included Studies and Primary Findings 
 
Study Agea Groups Mood State of BD Patients 
Diagnostic 
Criteria Primary Finding 
McNamara 
et al. 2016 
9 – 20 BD I (1st 
episode) 
and HC 
Mixed/Manic 
Episode 
DSM-IV Omega-3 index was significantly 
lower in BD and at-risk groups 
compared to healthy controls. 
EPA + DHA level is associated 
with mood symptom severity. 
Clayton et al. 
2008 
8 – 18 BD 
I/II/NOS 
and HC 
Mood episode 
within the last 6 
mo. 
DSM-IV-
TR 
Adolescents with BD did not 
have significantly different levels 
of EPA or DHA compared to 
healthy controls after controlling 
for dietary intake. DHA level was 
related to symptoms of 
depression. 
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Table 1. (continued) 
Study Agea Groups Mood State of BD Patients 
Diagnostic 
Criteria Primary Finding 
Newton et al. 
2017 
13 – 20 BD 
I/II/NOS 
and HC 
Symptomatic 
and 
Asymptomatic 
DSM-IV Negative association between 
LPH and executive function in 
BD adolescents which may be 
modulated by BDNF. 
Hatch et al. 
2015 
13 – 19 BD 
I/II/NOS 
Symptomatic 
and 
Asymptomatic 
DSM-IV Adolescents with BD have lower 
levels of oxidative stress than 
adults with BD. 
Hatch et al. 
2017 
13 – 19 BD 
I/II/NOS 
and HC 
Symptomatic 
and 
Asymptomatic 
DSM-IV Evidence of increased 
inflammation in adolescents with 
BD. 
Scola et al. 
2016 
9 – 20 BD I and 
HC 
Mixed or Manic 
Episode 
DSM-IV-
TR 
Syndromal BD in adolescents is 
associated with significantly 
decreased LPH compared to 
healthy controls. 
Miklowitz et 
al. 2016 
12 – 18 BD 
I/II/NOS, 
MDD and 
HC 
Euthymic DSM-IV-
TR 
Adolescents with BD had 
significantly greater NF-kb 
activation in peripheral blood 
mononuclear cells and higher 
levels of IL-1b compared with 
healthy controls. 
Goldstein et 
al. 2011 
12 – 19 BD 
I/II/NOS 
Symptomatic 
and 
Asymptomatic 
DSM-IV Mood symptoms in BD are 
associated with increased 
proinflammatory markers and 
decreased BDNF. 
Goldstein et 
al. 2015 
13.4 – 
28.3 
BD 
I/II/NOS 
Symptomatic 
and 
Asymptomatic 
DSM-IV Proinflammatory markers are 
associated with BD clinical 
characteristics in youth and young 
adults with BD. 
Petrov et al. 
2018 
6 – 12 BD 
I/II/NOS, 
MDD and 
HC 
Unreported DSM-IV DBP was significantly greater in 
BD group compared to healthy 
controls. 
Cevher 
Binici et al. 
2018 
16.42 ± 
1.29 
BD I and 
HC 
Euthymic DSM-IV-
TR 
No significant difference in NLR 
and PLR between BD adolescents 
and healthy controls. 
Ceylan et al. 
2018 
14 – 17 BD I 
and HC 
Euthymic DSM-V Prolidase activity and monocyte 
count were significantly greater in 
BD group compared to healthy 
controls. 
 
Note: BD = participants diagnosed with bipolar disorder I, II, or not otherwise specified 
(NOS). HC = healthy control group. MDD = participants diagnosed with major 
depressive disorder. LPH = lipid hydroperoxides. DBP = vitamin d binding protein. NLR 
= neutrophil-to-lymphocyte ratio. PLR = platelet-to-lymphocyte ratio. 
a Reported as range or mean ± standard deviation.
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Omega-3 Fatty Acids and Oxidative Stress 
Oxidative stress refers to an imbalance in the pro-oxidant and antioxidant species 
in the body. This imbalance can lead to cell, tissue and organ damage. In particular, 
reactive oxygen species can damage lipids, proteins and DNA. The primary sources of 
reactive oxygen species are the mitochondria, peroxisomes, endoplasmic reticulum, as 
well as the structural components of the cell such as the plasma membrane (Di Meo, 
Reed, Venditti, & Victor, 2016). Lipid peroxidation occurs when free radicals or 
nonradical oxidant species attack lipids containing carbon-carbon double bonds, 
especially polyunsaturated fatty acids. Eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are essential long-chain omega-3 polyunsaturated fatty 
acids that are important for brain development and have anti-inflammatory, neurotrophic 
and neuroprotective effects (Horrobin & Bennett, 1999; McNamara, Vannest, & 
Valentine, 2015). DHA, in particular, is the most prominent omega-3 fatty acid in neural 
tissue, and increases in either plasma or tissue DHA or EPA content can be achieved with 
dietary supplementation of the respective fatty acid (Arterburn, Hall, & Oken, 2006). As 
reviewed elsewhere, several studies have evaluated fatty acid supplementation as a 
monotherapy or adjunctive therapy for symptom improvement in affective disorders. It 
seems that fatty acid supplementation is more promising as a monotherapy or adjunctive 
in major depressive disorder (MDD) compared to BD, but there is evidence that fatty acid 
supplementation may have a positive effect, particularly on depressive symptoms, in BD 
that warrants further study (Ciappolino et al., 2017). Long-chain omega-3 
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polyunsaturated fatty acids were measured in two of the identified studies with differing 
results.  
McNamara and colleagues (2016) evaluated the levels of EPA and DHA in the 
erythrocytes of adolescents with or at risk for BD to assess long-chain omega-3 
polyunsaturated fatty acid biostatus as a potential prodromal risk biomarker. Study 
participants included four groups of adolescents ranging in age from 9 to 20 years. The 
first group consisted of healthy comparison (HC) participants without a diagnosis or 
family history of a DSM-IV Axis I disorder (n=28). The second group included 
participants without a personal diagnosis of a DSM-IV Axis I disorder, but with at least 
one biological parent that had been diagnosed with BD-I (high risk; HR, n=30). The third 
group consisted of participants with at least one biological parent with BD-I and a 
personal DSM-IV Axis I diagnosis of MDD or depressive disorder not otherwise 
specified (ultra-high risk; UHR, n=36). The fourth group consisted of participants with a 
DSM-IV Axis I diagnosis of BD-I (BP, n=35) exhibiting first-episode mixed or manic 
symptoms. Patients with BD were medication-free at the time their blood was drawn.  
 Mean erythrocyte EPA+DHA composition was significantly lower in the BP and 
UHR groups compared to healthy controls. Similar decreases in DHA and EPA were 
found in adult BD patients (Chiu et al., 2003; Ranjekar et al., 2003). Additionally, 
compared with healthy controls (61%), a significantly greater portion of adolescents at 
high risk (77%), ultra-high risk (81%) or in the first episode of BD (97%) had an omega-
3 index that was ≤ 4.0%. Omega-3 index is a measure of two prominent long-chain 
omega-3 fatty acids (EPA and DHA) in a person’s red blood cells. It is expressed as a 
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percentage of the total erythrocyte fatty acid composition. An omega-3 index ³ 8% is 
considered cardioprotective whereas an omega-3 index £ 4% is associated with greater 
cardiovascular risk (Harris & von Schacky, 2004). This is relevant because patients with 
BD have an increased risk of death from cardiovascular disease (Ösby, Brandt, Correia, 
Ekbom, & Sparén, 2001). This connection may be related to the chronic low-grade 
inflammation found in both, but further studies are needed (Rosenblat & McIntyre, 
2015).   
Of note, significantly more patients with BD and participants at risk for BD in the 
study had a history of ADHD compared to healthy control participants. This speaks to the 
prevalence of co-morbid ADHD in youth with BD. The level of EPA+DHA were 
significantly lower in all subjects with ADHD (n=34) compared with healthy controls.  
However, group differences in EPA+DHA level could not be attributed to age, body mass 
index (BMI), race, smoking status, or comorbid ADHD. Among all subjects (n=130), 
EPA+DHA composition level was inversely correlated with mania symptoms, according 
to total scores on the Young Mania Rating Scale (Young, Biggs, Ziegler, & Meyer, 
1978), and depressive symptoms, according to total scores on the Hamilton Rating 
Depression Scale (Hamilton, 1960).  
The association of EPA+DHA composition and mood symptoms, taken together 
with the more prominent omega-3 index deficiency observed in BP > UHR > HR groups 
compared to the healthy control group, suggests that erythrocyte EPA+DHA biostatus 
represents a candidate for a prodromal risk biomarker (McNamara et al., 2016). An 
important limitation of this study was the absence of a measure for dietary habits. EPA 
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and DHA are essential fatty acids meaning that they must be obtained from the diet, so 
dietary intake could be a covariable for omega-3 fatty acid biostatus. This was addressed 
in the second study to measure fatty acid biostatus in youth with BD. 
 Similar to the previous study, Clayton and colleagues (2008) measured plasma 
and red blood cell (RBC) concentrations of EPA and DHA. Participants were aged 8 to 
18 years with a diagnosis of BD I, II, or NOS based on criteria set forth in the Diagnostic 
and Statistical Manual of Mental Disorders 4th edition, Text Revision (DSM-IV-TR). 
Patients with BD reported a mood episode within the last 6 months and were stabilized 
for at least 4 weeks on medication. Healthy age-matched controls with no personal or 
first-degree family history of a mood disorder were also included. In contrast to the 
previous study, they found that RBC concentrations of EPA and DHA were not 
significantly lower in adolescent BD patients after controlling for daily intake using a 
food frequency questionnaire. The omega-3 index was not significantly different between 
groups, and all were at a medium risk level for cardiovascular disease (CVD) (between 4-
8%). Regarding mood symptoms, the study found that RBC DHA concentration was 
inversely related to clinician’s ratings of depression and the relationship reached 
statistical significance. Plasma EPA was significantly associated with symptoms of 
mania, externalizing and disruptive behaviors, but RBC EPA was not significantly related 
to any psychological measures. This provides some support to the association between 
fatty acid composition and mood symptoms in youth patients with BD. Omega-3 
polyunsaturated fatty acids can have mood stabilizing effects through various proposed 
mechanisms including affecting cell membrane fluidity and signal transduction (Clayton, 
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Hanstock, Garg, & Hazell, 2007). The study authors also bring attention to the prevalence 
of low socioeconomic status and deficient dietary omega-3 fatty acid intake among youth 
with BD. Given the association between lower DHA composition and symptoms of 
depression, they suggest that youth with BD may benefit from omega-3 fatty acid 
supplementation (Clayton et al., 2008). This study addressed the need for dietary fatty 
acid intake to be a covariate during analysis. However, it differs from the above study in 
regard to the medication status of participants with BD. Participants in the study by 
Clayton et al. did not show significant differences in EPA, DHA or arachidonic acid 
levels based on receiving lithium or valproate as their primary mood stabilizing 
medication.  However, no comparison was drawn with a medication-free patient cohort. 
Understanding the association between medication status and fatty acid biostatus will be 
important when considering fatty acid supplementation as an adjunctive or monotherapy 
in youth with BD. 
 Polyunsaturated fatty acids have an antioxidant effect that is protective (Richard, 
Kefi, Barbe, Bausero, & Visioli, 2008), but they are still susceptible to lipid peroxidation 
given their multiple carbon-carbon double bonds. This is significant given the abundance 
of DHA and EPA in the brain. The first two studies addressed fatty acid biostatus but did 
not explore oxidation of those vulnerable fatty acids. As mentioned above, oxidative 
stress refers to an imbalance in anti-oxidant and pro-oxidant species. Several studies 
support the hypothesis that oxidative stress is involved in the pathophysiology of BD, 
especially lipid peroxidation (N. C. Brown, Andreazza, & Young, 2014).  
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 Newton and colleagues (2017) explored the association between lipid 
peroxidation and executive dysfunction in adolescent patients with BD and what impact 
BDNF had on the relationship. BDNF is a protein that binds to the Trk B receptor (a 
tyrosine kinase) and has several intracellular and transcriptional effects that promote 
neuronal cell growth, development and plasticity. It has been implicated as a risk factor 
for BD and cognitive dysfunction (Post, 2007). Trophic factors will be further discussed 
in a later section. In addition to measuring serum BDNF, they also measured serum levels 
of lipid hydroperoxides (LPH) which is the main product of lipid peroxidation and 4-
hydroxy-2-nonenal (4-HNE) which is a secondary product of LPH oxidation. Executive 
functioning was measured using the intra-extra dimensional set shift (IED) task from the 
Cambridge Neuropsychological Test Automated Battery (CANTAB). The CANTAB is a 
collection of tests that assess different aspects of cognitive function (Sahakian & Owen, 
1992). Participants ranged in age from 13 to 20 years and included participants with a 
DSM-IV diagnosis of BD I (n=6), a DSM-IV diagnosis of BD-II (n=13) or BD-NOS 
(n=10) as defined by the Course and Outcome of Bipolar Youth (COBY) study criteria 
(Axelson et al., 2006) for a total of 29 BD participants. Participants with BD did report 
medication usage. The cohort also included healthy control participants with no diagnosis 
of BD nor any first/second degree relatives with a BD/psychosis diagnosis (n=25).  
They found that there were no significant differences in serum LPH, 4-HNE, or 
BDNF levels between the BD and healthy control groups. LPH and BDNF were 
significantly and positively correlated in the HC group. They were negatively correlated 
in the BD group, but this correlation did not reach significance. The difference in 
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correlation between the two groups was significant. LPH was associated with poorer IED 
performance (defined by higher raw score on completed stage trials of the IED task) in 
BD participants with high BDNF levels. LPH was associated with better performance 
(defined by lower raw score on total trials of the IED task) in HC participants with low 
BDNF. Studies have shown that BDNF gene expression is normally increased in 
response to oxidative stress (Sakr, Abbas, & Samanoudy, 2015). Among adult BD 
patients, however, peripheral levels of BDNF are shown to be decreased and correlated to 
cognitive impairment (Bauer, Pascoe, Wollenhaupt-Aguiar, Kapczinski, & Soares, 2014; 
Cunha et al., 2006). The authors suggest that the contrasting correlation seen in BD 
versus control participants may point to a disturbance in the interaction between the two 
pathways, and that LPH and BDNF are illness activity biomarkers of interest regarding 
executive function in BD (Newton et al., 2017).  
Additionally, the staging hypothesis of BD suggests that BDNF levels would be 
more severely impacted with recurrent affective episodes and are found to be decreased 
in patients with late-stage versus early-stage BD (Kauer-Sant’Anna et al., 2009). Thus, 
the lack in significantly different BDNF levels in BD versus HC adolescents could be 
associated with the short illness duration of adolescent patients. A limitation of this study 
was that the average age was higher among BD participants and average IQ was greater 
among healthy controls. Propensity score was used to control for the influences of age, 
IQ, comorbid ADHD, BMI and tobacco use. Larger, longitudinal studies with age and 
IQ-matched controls will need to further investigate the association between oxidative 
stress and executive function, and how BDNF may interact with this relationship.  
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 Hatch and colleagues (2015) set out to examine psychiatric and cardiovascular 
characteristics as they were associated with peripheral biomarkers of oxidative stress. As 
mentioned above, cardiovascular disease contributes to the excess mortality seen in adults 
with BD. Studies also support a role of oxidative stress in the development of 
cardiovascular diseases (Madamanchi Nageswara R., Vendrov Aleksandr, & Runge 
Marschall S., 2005). They measured serum levels of LPH and protein carbonylation (PC) 
to gauge oxidative stress. Protein carbonyls are formed when reactive oxygen species 
react with side chains of proteins; they are reliable measures of oxidative stress that have 
been associated with BD (N. C. Brown et al., 2014; Dalle-Donne, Rossi, Giustarini, 
Milzani, & Colombo, 2003). They performed an ultrasound to measure flow mediated 
dilation (FMD) and carotid intima media thickness (cIMT) which are indicative of 
atherosclerosis and CVD risk (Urbina et al., 2009). They also measured blood pressure, 
pulse pressure, and fasting glucose, triglyceride, total cholesterol, high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL) levels. Study participants were 
aged 13 to 19 years and had a DSM-IV diagnosis of BD-I (40%), a DSM-IV diagnosis of 
BD-II (40%) or BD-NOS based on COBY study criteria (20%). A healthy adolescent 
control group was not included. Participants did not have a diagnosis of any cardiac, 
autoimmune, infectious, or inflammatory illnesses. Comorbidity for other psychiatric 
illnesses, such as ADHD, were not reported. Thirty-two percent of participants reported 
medication usage. 
 The study found that oxidative stress markers were significantly lower among the 
participants compared to those reported in adults with BD in a separate study (Andreazza 
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et al., 2009). There were no significant associations between oxidative stress markers 
(LPH and PC) and mood (depression and mania) symptom severity, duration of illness or 
age at onset. However, no participants met the criteria for mania, 76.7% were 
asymptomatic in terms of hypomania and 50% were asymptomatic in terms of depression 
at the time of the study. Greater cIMT measurements were associated with greater 
oxidative stress, as measured via serum LPH levels (but not significantly associated with 
PC). Neither LPH nor PC was significantly associated with FMD levels. Oxidative stress 
was associated with other markers of CVD risk. For instance, greater PC was associated 
with lower levels of HDL and greater levels of LPH were associated with pulse pressure. 
The authors conclude that oxidative stress is less severe in youth versus adults with BD, 
but it is still a risk biomarker for comorbid CVD later in adulthood (J. Hatch et al., 2015).  
Scola and colleagues (2016) focused on levels of lipid peroxidation and 
inflammatory biomarkers in adolescents with and at-risk for BD-I. Participants were aged 
9 to 20 years old and fell into one of four categories: 1) healthy controls (HC) with no 
personal or family history of psychiatric illness (n=13); 2) high risk (HR) participants 
with no psychiatric illness but with a parent that has BD-I (n=15); 3) ultra-high risk 
(UHR) participants with at least one parent with BD-I and with a personal diagnosis of 
MDD or depressive disorder not otherwise specified (n=20); 4) first-episode BD patients 
exhibiting mixed or manic symptoms that received a DSM-IV-TR diagnosis of BD-I 
(n=16). With the exception of psychostimulants for participants with an ADHD 
diagnosis, all patients were off of psychotropic medication at the time blood was taken. 
Blood was taken prior to initial treatment in first-episode BD patients, and participants in 
	26 
the ultra-high risk category were off of anti-depressants for at least 5 days (1 month for 
fluoxetine) prior to blood draw.  
Lipid peroxidation was measured using plasma levels of LPH, 4-HNE and 8-
isoprostane (8-ISO). 8-isoprostane is a secondary product from the oxidation of 
arachidonic acid, a polyunsaturated omega-6 fatty acid (Montuschi, Barnes, & Roberts, 
2004). Protein oxidation was also measured using plasma PC content. Inflammation was 
measured using plasma levels of cytokines IL-1α, IL-1b, IL-6, IL-10, IFN γ and TNF-α. 
Inflammation is a key component in the pathophysiology of BD which will be explored 
in a later section. Additionally, vascular endothelial growth factor (VEGF) was measured.  
LPH levels (early stage lipid peroxidation) in BD patients were found to be 
significantly lower than that of healthy controls. This was in contrast to adult findings 
wherein LPH levels were higher among BD patients compared to healthy controls 
(Versace et al., 2014). The at-risk groups did not have significantly different LPH levels 
compared to healthy controls. Interestingly, the ratio (4HNE + 8ISO)/LPH level was 
significantly higher in BD patients compared to that in healthy controls which is 
consistent with LPH being converted into 4HNE and 8-ISO (two late stage markers of 
lipid peroxidation). Within the BD group, manic symptom severity was positively 
correlated with LPH and negatively correlated with 8-ISO/LPH and (4-HNE+8-
ISO)/LPH ratios. The authors suggests that this may be evidence for a greater conversion 
of LPH to late stage markers of lipid peroxidation among adolescents with BD (Scola et 
al., 2016). There were no significant differences in PC content, VEGF or inflammatory 
markers.  
	27 
Other factors for possible exploration of protein and lipid oxidation in adolescents 
with BD include nitric oxide, 3-Nitrotyrosine which is an end product of nitrosative 
damage to a tyrosine residue, thiobarbituric acid reactive substance, and malondialdehyde 
which may be related to the pathophysiology of BD as reported in studies on adult 
patients (Muneer, 2016a; Scola & Andreazza, 2014). This could provide further 
information to evaluate the efficacy of each as a biomarker for BD in youth and help to 
explain whether and why levels might differ in youth versus adults. 
 
Neurotrophic Factors 
Neurotrophins are small secreted proteins that are crucial to neuronal cellular 
dynamics and brain function. They mediate central and peripheral connections, regulate 
cell fate, manage synaptic function by controlling expression of the proteins that 
comprise neurotransmitters and ion channels, and ensure plasticity (Huang & Reichardt, 
2001). They also play important roles outside of the central nervous system including 
maintenance of immune cells (Sariola, 2001). The nerve growth factor family of 
neurotrophins include BDNF, nerve growth factor (NGF) and neurotrophins 3 and 4/5 
(NT3 and NT4/5). They each initiate cellular changes after binding to one of the TrK 
receptors or the p75 neurotrophic receptor (p75NTR). After binding the TrK family of 
receptors they have downstream effects that are anti-apoptotic which makes them vital 
for cell survival and development. They have less affinity for the p75NTR receptors and 
after binding these receptors they tend to have effects that disrupt axonal growth and lead 
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to programmed cell death, in part determining which neurons survive during development 
(Huang & Reichardt, 2001). 
Neurotrophins, particularly BDNF, create a systemic response when present in 
unbalanced levels and this seems to be associated with the pathophysiology of BD. There 
are other trophic factors that bind to different receptors but exert their cellular effects in a 
similar way. These include glial cell line-derived neurotrophic factor (GDNF), insulin-
like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF). As 
reviewed previously, all of the mentioned trophic factors have been studied in an effort to 
elucidate their involvement in adult BD pathophysiology. Differences in trophic level 
based on BD diagnosis, BD mood state, early versus late stage illness and mood-
stabilizing medication usage have been observed with BDNF, GDNF, IGF-1 and VEGF 
having the most support as biomarkers of BD in adults (Scola & Andreazza, 2015). 
BDNF is the most abundant neurotrophin and has predictably been the most studied. 
Several studies in adults with BD have found that BDNF level is generally lower in 
patients than in healthy controls during affective episodes, but similar to healthy controls 
during euthymia (Fernandes et al., 2011). Three studies measured BDNF in youth and 
two compared those levels with healthy controls. As mentioned previously, Newton et al. 
(2017) did not find a significant difference in BDNF level between adolescents with BD 
and healthy controls.  
In a 2011 study, Goldstein and colleagues completed one of the first studies to 
look at serum BDNF and proinflammatory cytokines (IL-6 and C-reactive Protein, CRP) 
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among adolescents with BD. IL-6 is a cytokine released by various immune cells. It leads 
to the release of CRP which is a protein produced in the liver and released as part of the 
inflammatory response. Several studies have identified IL-6 and CRP as relevant 
inflammatory biomarkers of BD, particularly as it relates to the cognitive impairment 
seen in the disorder (Bauer et al., 2014; Sayana et al., 2017). Thirty participants aged 12 
to 19 years were enrolled in the study. Eighteen participants were diagnosed with DSM-
IV BD-I, one participant was diagnosed with DSM-IV BD-II, and eleven participants 
were diagnosed with BD-NOS according to criteria set forth in the COBY study. Sixty-
three percent of the participants were in the midst of a full-threshold or clinically 
significant subthreshold symptomatic interval. Participants reported various medication 
usage including second-generation antipsychotics, lithium or divalproex sodium, 
psychostimulants or antidepressants.  
Investigators found that BDNF was not significantly associated with manic or 
depressive symptom severity. BDNF levels were significantly, negatively associated with 
IL-6. This association was reduced to a trend after controlling for obesity. Manic 
symptom severity was significantly, positively associated with CRP but was not 
associated with IL-6. This association between manic symptom severity and levels of 
CRP matched that observed in adult BD outpatients (Dickerson, Stallings, Origoni, 
Boronow, & Yolken, 2007). Depressive symptom severity was not significantly 
associated with CRP or IL-6. Of note, 40% of participants had levels of CRP that were 
considered at-risk for CVD in adulthood (Ridker et al., 2008). Further highlighting the 
need for intervention in the early stage of the disorder to prevent severe comorbidities in 
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adulthood. This study did not include a healthy age-matched control group. Thus, even 
though BDNF level in this sample was not associated with symptom severity there was 
no analysis to evaluate if these participants had a BDNF level that was similar or 
different from that in healthy youth.  
In a separate 2017 study, Hatch and colleagues evaluated BDNF and 
inflammatory markers (IL-6 and tumor necrosis factor alpha, TNF-a) as they related to 
CVD risk in adolescents with BD. TNF-a and IL-6 are both cytokines involved in the 
immune response. Participants were aged 13-19 years old. There was a total of 40 
participants that were diagnosed with DSM-IV BD-I (n=14) or bipolar II disorder (n=16) 
or were diagnosed with BD-NOS (n=10) according to the COBY study criteria. Of those 
with BD, 19 participants were symptomatic and 21 were asymptomatic. Several were on 
mood stabilizing medication at the time. The study also included a healthy control (HC) 
group (n=20) with no personal or family history of BD, psychosis or substance abuse 
disorder. 
The study found that CVD risk factors were not significantly associated with 
proinflammatory markers or BDNF in BD participants. There were no significant 
differences in cIMT or FMD between groups. Nor was there a significant difference in 
BDNF between groups. Lower BDNF levels were associated with significantly thicker 
mean cIMT among adolescents with symptomatic BD only. BD participants had greater 
waist circumference, BMI, pulse pressure and IL-6 levels compared to healthy controls. 
IL-6 remained significantly greater after controlling for age and BMI. Symptomatic BD 
participants had the greatest IL-6 level followed by asymptomatic BD participants and 
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healthy controls had the lowest IL-6 level. TNF-a was significantly greater in BD 
participants than in healthy controls and remained significant after controlling for BMI 
and age. The observation of increased IL-6 and TNF-a in BD patients, especially those 
who are symptomatic, compared to controls matches that often seen in adult BD studies 
(Goldstein, Kemp, Soczynska, & McIntyre, 2009). The findings in this study provide 
preliminary support for the conception of BD as a multi-systemic disease and the lack of 
significant difference in cIMT and FMD between healthy controls and BD participants 
points to a window of opportunity to intervene and prevent comorbid CVD in this 
population (J. K. Hatch et al., 2017).  
Interestingly, the BDNF val66met polymorphism has been found to be relevant to 
BD in youth (Geller et al., 2004). However, there is conflicting accounts on whether 
circulating BDNF is associated with the BDNF polymorphisms. On one hand, studies 
have found a significant association between serum BDNF concentration and the 
Val66Met genotype (Lang, Hellweg, Sander, & Gallinat, 2009). On the other hand, a 
meta-analysis on the topic rejected the hypothesis that the Val66Met variant has a direct 
effect on serum BDNF (Terracciano et al., 2013). It may be beneficial to simultaneously 
evaluate genetic/epigenetic changes and peripheral BDNF in youth with BD to further 
explore this association. Additionally, youth BD studies are needed that evaluate other 
neurotrophic factors of relevance.
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Inflammation and Immune Disturbances 
 The immune system functions to protect the host from pathological invasion. One 
of the components in this system is inflammation which functions to clear out the invader 
and facilitate repair of damaged cells. Cytokines are small proteins that mediate this 
inflammatory process. Patients with BD often have comorbid illnesses such as 
autoimmune diseases, cardiovascular diseases, and metabolic dysfunctions including 
obesity and diabetes, all of which have been associated with an underlying immune 
disturbance (Rosenblat & McIntyre, 2015). Inflammatory markers have been extensively 
studied in adult BD leading to a common characterization of mood episodes as pro-
inflammatory states (Frey et al., 2013; Muneer, 2016a). There is evidence that 
inflammation and immune dysfunction are present in BD, but inflammatory markers are 
moderated by additional factors such mood state, duration of illness and medication 
usage requiring further validation (Sayana et al., 2017). Similar to the literature on adult 
BD, research on inflammation and immune disturbance makes up a large portion of the 
studies on BD in youth. Several of the previously discussed youth studies included one or 
more measures of inflammation. The following studies examined inflammation and 
immune disturbance as the primary target for biomarker development.  
 Miklowitz and colleagues (2016) examined plasma levels of proinflammatory 
(IL-1β, IL-6, IL-8, TNF-a) and anti-inflammatory (IL-10) cytokines in adolescents with 
BD and MDD. They also examined Nuclear Factor – Kappa Beta (NF-kb) signaling in 
spontaneous or stimulated (after incubation with TNF-a) peripheral blood mononuclear 
cells. NF-kb is a transcription factor that controls gene expression of proinflammatory 
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cytokines. Participants were aged 12 to 18 years old with a DSM-IV-TR diagnosis of 
BD-I (N=7), BD-II (N=5), BD-NOS diagnosis according to COBY study criteria (N=6) 
or a DSM-IV-TR diagnosis of MDD (n=13). Participants with no psychiatric history were 
included as healthy controls (n=20). BD and MDD adolescents were in remission or had 
subsyndromal symptoms and were on various medication regimens. 
 There were significantly higher levels of spontaneous NF-kb in total peripheral 
blood mononuclear cells of BD patients compared to healthy controls. NF-kb levels were 
also higher when measured in a subpopulation of only monocytes and only lymphocytes. 
There were significantly higher levels of stimulated NF-kb in total peripheral blood 
mononuclear cells of BD patients compared to healthy controls. In the monocyte-only 
subpopulation analysis, stimulated NF-kb was higher among both BD and MDD patients 
compared to healthy controls. This study’s findings of increased NF-kb activation were 
consistent with that observed in euthymic adults (Barbosa et al., 2013). Of note, the 
aforementioned study also observed significantly increased IL-6 (as well as increased IL-
10 and TNF-a which were not significant) in adult euthymic BD patients compared to 
controls. IL-1β was the only proinflammatory cytokine observed at higher levels among 
adolescent BD patients compared to healthy controls in the current youth study. There 
were no significant differences in IL-10 between the groups. MDD participants did not 
significantly differ from BD patients or healthy controls for any cytokine level. Higher 
levels of stimulated NF-kb in monocytes was significantly, positively correlated with 
depressive symptom severity among the BD group and MDD group. Cytokine levels 
were not significantly associated with mood symptom severity in any of the diagnostic 
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groups. The study authors suggests that NF-kb is a target biomarker for early intervention 
in youth with BD (Miklowitz et al., 2016).  
In a later 2015 publication on COBY study participants, Goldstein and colleagues 
examined multiple pro-inflammatory markers (PIMs) and their relations to various 
clinical characteristics among adolescents and young adults with BD. Participants were 
aged 7 years 0 months to 17 years 11 months at the time of the intake assessment as part 
of the COBY study. At the time of the current analysis, participants were aged 13.4 to 
28.3 years and diagnosed with BD-I (58.5%), BD-II (6.5%) or BD-NOS (35%) (n=123).  
Twenty patients in the current analysis participated in the pilot study conducted by 
Goldstein and colleagues (2011) detailed previously but provided a new blood sample. 
Patients were on various medications and in various mood states at the time of collection. 
In addition to collecting information on clinical characteristics over the last six months, 
serum levels of IL-6, TNF-α, and CRP were also collected.  
Higher CRP was significantly associated with earlier BD onset age after false 
discovery rate correction. The study found that lifetime clinical characteristics were 
significantly associated with PIMs in multivariate analyses. In particular, lifetime suicide 
attempt and self-injurious behavior were associated with TNF-α. Duration of BD was 
associated with IL-6 and CRP. Comorbid substance use disorder was also associated with 
CRP. Clinical characteristics over the preceding 6 months were also associated with 
PIMs. The percentage of weeks with psychosis was associated with TNF-α, percentage of 
weeks with subthreshold mood symptoms and any suicide attempt were associated with 
IL-6, and maximum severity of depressive symptoms (but not manic symptoms as seen in 
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the previous study) was associated with CRP and IL-6. The study did not include a 
healthy control group. So, while the information does shed light on clinical characteristics 
and how they may be related to inflammation, it is not clear whether these associations 
are unique to BD. The authors suggest that proinflammatory markers are best suited as 
biomarkers of illness activity rather than as diagnostic biomarkers (Goldstein et al., 
2015). This stands to reason given the underlying inflammation seen in patients with both 
BD and various comorbid illnesses. 
 In a pilot study, Petrov and colleagues (2018) evaluated the levels of various 
markers of inflammation in youth with and without a mood disorder. IL-6, vitamin D, 
and NF-kb activation were measured and compared among groups. Additionally, they 
found that vitamin D binding protein (DBP) is a structural homolog of glia maturation 
factor beta (GMFb) in human plasma. GMFb is expressed in astrocytes and activates the 
microglia, which in turn release proinflammatory cytokines that could be disturbing the 
neuroprotective system (Thangavel, Stolmeier, Yang, Anantharam, & Zaheer, 2012). 
Since at any one time only 1- 2% of DBP is bound to vitamin D, it was suggested that 
DBP may have other functions that are relevant to a range of diseases (Gomme & 
Bertolini, 2004). Plasma samples of participants from the Longitudinal Assessment of 
Manic Symptoms Study were used (Findling et al., 2010). Participants were aged 6 to 12 
years and either had a DSM-IV diagnosis of BD with BD-NOS diagnosis being 
operationalized using COBY study criteria (n=12), MDD (n=11) or were healthy controls 
with no history of mood disorder diagnosis (n=13). Medication status was not reported. 
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 There were increased levels of DBP in participants with BD compared to the non-
mood control participants. The level of DBP in the MDD group was not significantly 
greater than that in the healthy control group. Other indicators of inflammation (IL-6, 
NF-kB activation) were not significantly elevated in participants with a mood disorder 
compared to healthy controls. They also found a significant correlation between IL-6 
level and obesity across all studied groups. Given these findings, the authors suggests that 
DBP may be a more appropriate marker of BD pathology than inflammatory cytokines 
because of its ability to discriminate BD participants in the sample (Petrov et al., 2018).  
 Cevher Binici and colleagues (2018) evaluated immune dysregulation in 
adolescents with BD by comparing neutrophil-to-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) in euthymic BD patients compared to healthy controls. 
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are accepted parameters of 
systemic inflammation (Balta & Ozturk, 2015; Zahorec, 2001). Participants were 36 
adolescents (16.42 years of age ± 1.29 years) diagnosed with DSM-IV-TR BD-I who 
were euthymic and 36 healthy controls (16.30 years of age ± 1.19 years) with no family 
history of psychiatric disorder in first degree relatives. Patients with BD had been on a 
medication regiment for an average of 2.1 years.  
 The study found that there were no significant differences in the NLR or PLR of 
euthymic BD patients vs healthy controls. This differed from findings in adult studies 
which found that NLR and PLR were higher in both manic and euthymic BD patients 
compared to healthy controls (Kalelioglu et al., 2015; Mert & Terzi, 2016). However, the 
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authors suggest that the current findings support the hypothesis that the inflammatory 
pathways are progressively perturbed with illness duration (Cevher Binici, Alşen Güney, 
& İnal Emiroğlu, 2018).  
The last study identified in the literature search was by Ceylan and colleagues 
(2018) and investigated the role of the immune system and prolidase activity in PBD. 
They measured the serum levels of prolidase and the level of peripheral blood 
mononuclear cells including monocytes, lymphocytes, neutrophils, lymphocyte-to-
monocyte ratio (LMR) and NLR. Prolidase is a multifunctional enzyme capable of 
splitting dipeptides when a proline or hydroxyproline residue is located at its c-terminal 
end making it important for the functional metabolism of proline-containing peptides in 
the brain (Hui & Lajtha, 1978). This is relevant as proline accounts for approximately 5% 
of amino acid residues of proteins in the brain (Lajtha & Toth, 1974). A previous study in 
adults with BD found that prolidase level was significantly greater in patients compared 
to healthy controls regardless of mood state (Selek, Altindag, Saracoglu, Celik, & Aksoy, 
2011). Participants in the study by Ceylan and colleagues were 14 to 17 years of age. 
Thirty-eight participants were diagnosed with BD-I according to DSM-V criteria and 
were euthymic at the time of study (n=38). Age and gender-matched healthy controls 
were also included (n=37). 
The study found that the prolidase level and monocyte count were significantly 
higher in adolescent BD-I patients compared to healthy age-matched controls, similar to 
the findings in adult BD patients. No significant differences in neutrophil or lymphocyte 
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count, LMR, or NLR were observed. There was no significant correlation between 
prolidase activity and monocyte, lymphocyte, or neutrophil counts, NLR, or LMR. Study 
authors propose that increased prolidase activity leads to increases in proline that 
subsequently increase glutamate levels and promote hyperexcitation of N-methyl-D-
aspartate receptors in BD (Ceylan, Tural Hesapcioglu, Kasak, Senat, & Erel, 2018).  
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CONCLUSION AND FUTURE DIRECTIONS 
 The pathophysiology of BD is multifactorial and not fully understood. It is 
suspected that BD involves a complex interaction of apoptosis, oxidative and nitrosative 
stress, neuroinflammation, perturbed signaling pathways and energy metabolism. All of 
which are associated with disturbed brain development, declining neuroplasticity, and 
brain atrophy in a bidirectional manner (Sigitova, Fišar, Hroudová, Cikánková, & 
Raboch, 2017). Biomarkers obtained through neuroimaging or in the periphery are giving 
new insights into these processes and will provide measures with which to identify 
prodromal states, diagnose BD, track illness activity and monitor treatment response. It is 
especially important to study BD in children and adolescents given the subtle differences 
in their illness presentation compared to adult-onset BD and the increased risk for poor 
prognosis in adulthood associated with early onset age, treatment delay and longer illness 
duration. Studies in youth with BD may hold the key to understanding the etiology and 
progression of BD given that they are closer to their illness onset, providing an 
opportunity to explore mechanisms of the disorder before they are affected by recurrent 
mood episodes and prolonged medication usage.  
 The current paper aimed to identify the peripheral blood biomarkers which have 
been studied thus far in children and adolescents with BD. Peripheral blood biomarkers 
are easily obtained and relatively inexpensive to measure. Several different peripheral 
blood biomarkers were measured across 12 studies including cytokines, peripheral blood 
cell counts, long-chain omega-3 and omega-6 fatty acids, metabolites of lipid and protein 
oxidation, markers of inflammation, and enzymes related to the inflammatory process. Of 
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the peripheral biomarkers that were evaluated in more than one study, there was 
consistency in the findings that BDNF, 4-HNE, 1L-6, IL-10 and NLR were similar 
among youth with BD and healthy controls. In contrast to adult findings, there generally 
was not significant decreases in BDNF, increases in oxidative stress products or increases 
in inflammatory markers among youth with BD compared to age-matched healthy 
controls. This supports the hypothesis that the imbalance in these biomarkers that 
contributes to severe impairment in BD is associated with prolonged illness duration. 
Thus, identifying which stage, ranging from “at-risk” to “late stage”, a person falls into 
can present better opportunities for intervention. One study (J. K. Hatch et al., 2017) did 
conclude that BD in youth was associated with increased pro-inflammatory markers IL-6 
and TNF-a. However, the two studies by Goldstein and colleagues (2011; 2015) found 
that pro-inflammatory markers were significantly correlated with mood symptom severity 
and clinical characteristics. Therefore, one possible explanation is that the participants in 
the study by Hatch et al. had a more severe illness course or were further from disease 
onset. No definitive conclusions can be drawn with so few data points. This inconsistency 
serves to emphasize the need for additional studies on BD in the youth population to aid 
in drawing consensus in the field.  
All of the studies were limited in that they reported cross-sectional findings and 
had small samples sizes. These aspects affected the ability of study authors to include 
covariables such as medication usage, illness duration and mood state in statistical 
analysis, and also inhibited any conclusions on causality from being drawn. Additionally, 
most studies were published within the last five years which highlights the novelty of 
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biomarker research in children and adolescents with BD and the need for additional, 
longitudinal studies that reproduce or refute the current findings.  	 Interestingly, no studies evaluated HPA axis function which is central to the stress 
response and has been implicated in the pathophysiology of BD (Belvederi Murri et al., 
2016). There were similarly no youth BD studies directly evaluating peripheral 
biomarkers of mitochondrial dysfunction. Mitochondria have important roles in energy 
metabolism, calcium homeostasis, apoptosis and the generation of reactive oxygen 
species. Several studies point to an underlying mitochondrial dysfunction involved in the 
pathophysiology of BD (Scaini et al., 2016). 	
In conclusion, the selection of studies on peripheral blood biomarkers of BD in 
children and adolescents is currently narrow with regard to the number and 
pathophysiological focus of completed studies. However, it has grown over the last 5 
years and will likely continue to grow and provide new insights and opportunities for 
intervention. Interpretations of current study findings were limited, but provided support 
for the staging hypotheses of BD. As larger, longitudinal studies with heterogeneous 
samples are completed, covariate analysis will be important to increase statistical power, 
directionality will begin to be established and findings will be more generalizable. 
Neuroimaging studies were not included in the current review, but have also provided 
vital information on the neurophysiology of BD in children and adolescents (DelBello, 
Adler, & Strakowski, 2006). Evaluating multiple types of biomarkers in studies, such as 
neuroimaging and peripheral markers, could be useful to gain a more comprehensive 
understanding of BD pathophysiology. Ultimately, development of reliable peripheral 
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blood biomarkers will contribute to the understanding of illness onset and progression, 
early diagnosis and intervention, illness activity monitoring and development of 
therapeutics for youth and adults with BD. 	
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